Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma (FLORAL)

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Metastatic Urothelial Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT07339878

9770 (Other Identifier)

Details and patient eligibility

About

The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients over 18 years of age
• Metastatic urothelial carcinoma
• Treated with first-line metastatic therapy since October 2024

Exclusion criteria

• Patient who expressed opposition to participating in the study